[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100471268":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":24,"locations":18,"responsibleParty":34,"collaborators":38,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":18,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":18,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":74,"whyStopped":18,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":18},{"fullName":5,"class":6},"New York State Psychiatric Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"The Antipsychotic Medication Decision Aid (APM-DA) intervention clinics","EXPERIMENTAL","Three pairs of comparable clinics (out of 22 clinics where OnTrackNY operates) based on the same region of the state and similar numbers of patients with similar demographic composition. One of each paired clinic is assigned to the intervention group by a blinded Co-I who will generate binary random variables.",[13],"Other: The Antipsychotic Medication Decision Aid (APM-DA)",{"label":15,"type":16,"description":17,"interventionNames":18},"Treatment As Usual (TAU) clinics","NO_INTERVENTION","The other clinic of each of the three pairs will be assigned to TAU.",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":18},"The Antipsychotic Medication Decision Aid (APM-DA)","The APM-DA intervention is the first and only International Patient Decision Aid Standards (IPDAS) approved shared decision making (SDM) decision aid intervention for Antipsychotic Medication decisions in psychiatric visits. The APM-DA intervention developed by the research team addresses a common issue among psychiatric care providers and patients that lies in the heart of pharmacotherapy - taking, tapering or stopping APM. The APM-DA has a print format and can be used online as a PDF. It includes a concise table describing what each option involves, its benefits, risks, and strategies to reduce risks. The intervention was developed in co-production with various stakeholders (patients, clinicians, service leadership, family members, researchers). Additional intervention materials are an evidence document to support the information and an APM side effects table.",[9],[25,30],{"name":26,"role":27,"phone":28,"phoneExt":18,"email":29},"Lisa Dixon, MD, MPH","CONTACT","646-774-8420","lisa.dixon@nyspi.columbia.edu",{"name":31,"role":27,"phone":32,"phoneExt":18,"email":33},"Yaara Zisman-llani, MA, PhD","215-204-8726","yaara@temple.edu",{"type":35,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Lisa Dixon","Edna L. Edison Professor of Psychiatry",[39],{"name":40,"class":6},"Temple University","100471268","shared-decision-making-for-antipsychotic-medications-100471268",false,"NCT05416658","Shared Decision Making for Antipsychotic Medications","Examining the Effectiveness of a Shared Decision Making Intervention for Antipsychotic Medications to Improve Engagement in Treatment for People Experiencing Early Psychosis","Inclusion Criteria:\n\n* Ages 18 to 30 who have experienced nonaffective psychosis with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, other specified\u002Funspecified schizophrenia spectrum and other psychotic disorders (ICD-10-CM Diagnosis Code F20.x)\n* Current\u002Fpast experiences with antipsychotic medications (APM; e.g., currently taking any antipsychotic medication, stopped taking, or considering stopping).\n* Receive FEP treatment in one of OnTrackNY clinics\u002Fsites randomized to intervention or treatment as usual (TAU) - Willing to participate in research interviews after each APM visit during the study period (3 months)\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* No experience with APM\n* Not fluent (speaking, reading, writing) in English","ALL","18 Years","30 Years",{"count":52,"type":53},120,"ESTIMATED","INTERVENTIONAL",[56],"NA","This study aims to provide an evidence-based shared decision making intervention for antipsychotic medications, the Antipsychotic Medication Decision Aid (APM-DA), for individuals experiencing early psychosis and provide, for the first time, an understanding of the shared decision making mechanism of action.",[59,60,61,62,63],"Schizophrenia","Schizoaffective Disorder","Schizophreniform Disorders","Delusional Disorder","Other Specified Schizophrenia Spectrum and Other Psychotic Disorder",[65,66,67,68,69,70,71,72,73],"Shared decision making","psychosis","schizophrenia","antipsychotic","medication","intervention","decision aid","coordinated specialty care (CSC)","randomized controlled trial (RCT)","NOT_YET_RECRUITING","2026-03-24",{"date":77,"type":78},"2026-03-30","ACTUAL",{"date":80,"type":53},"2027-01-01",{"date":82,"type":53},"2027-06-30",{"name":5,"class":6}]